GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics Inc (MEX:SMMT) » Definitions » Cyclically Adjusted Price-to-FCF

Summit Therapeutics (MEX:SMMT) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Summit Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Summit Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Summit Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics Cyclically Adjusted Price-to-FCF Chart

Summit Therapeutics Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Summit Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Summit Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Summit Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Summit Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Summit Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Summit Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Summit Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Summit Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Summit Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-1.707/134.9266*134.9266
=-1.707

Current CPI (Mar. 2025) = 134.9266.

Summit Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201504 -1.758 99.824 -2.376
201507 -1.289 100.691 -1.727
201510 -1.737 100.346 -2.336
201601 -2.146 99.957 -2.897
201604 -2.611 100.947 -3.490
201607 -0.987 101.524 -1.312
201610 10.496 101.988 13.886
201701 -2.283 102.456 -3.007
201704 -3.257 103.167 -4.260
201707 3.522 103.278 4.601
201710 -4.013 104.070 -5.203
201801 -2.325 104.578 -3.000
201804 -2.358 105.708 -3.010
201807 -3.125 106.324 -3.966
201810 -1.159 106.695 -1.466
201901 -4.194 106.200 -5.328
201904 0.213 107.818 0.267
201907 -1.241 108.250 -1.547
201910 -1.033 108.577 -1.284
202003 -1.798 108.902 -2.228
202006 -6.408 108.767 -7.949
202009 -5.485 109.815 -6.739
202012 -2.088 109.897 -2.564
202103 -5.111 111.754 -6.171
202106 -4.178 114.631 -4.918
202109 -4.895 115.734 -5.707
202112 -1.946 117.630 -2.232
202203 -2.753 121.301 -3.062
202206 -2.801 125.017 -3.023
202209 -0.822 125.227 -0.886
202212 0.352 125.222 0.379
202303 -0.628 127.348 -0.665
202306 -0.720 128.729 -0.755
202309 -0.373 129.860 -0.388
202312 -0.471 129.419 -0.491
202403 -0.713 131.776 -0.730
202406 -0.856 132.554 -0.871
202409 -0.823 133.029 -0.835
202412 -1.377 133.157 -1.395
202503 -1.707 134.927 -1.707

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Summit Therapeutics  (MEX:SMMT) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Summit Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Summit Therapeutics Business Description

Traded in Other Exchanges
Address
601 Brickell Key Drive, Suite 1000, Miami, FL, USA, 33131
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.